Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apilimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE known ✓ | Q9Y2I7 | 5/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apilimod SCHEMBL29365634 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL29387519 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL29459498 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL426300 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL18121499 | 0.97 | PIKFYVE (0.94) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL20507067 | 0.97 | PIKFYVE (0.94) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL18115419 | 0.96 | PIKFYVE (0.92) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL18115421 | 0.96 | PIKFYVE (0.92) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL3082382 | 0.95 | PIKFYVE (0.91) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL3082380 | 0.95 | PIKFYVE (0.91) | PIKFYVETYK2SYKIRAK4FES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144107-A1 | USE OF A PIKFYVE INHIBITOR IN COMBINATION WITH IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-05-08 | — | — | US | claimed |
| US-20210404004-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2021-12-30 | — | — | US | claimed |
| US-20210140945-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES AND DISORDERS | MADRIGAL PHARMACEUTICALS INC (US) | 2021-05-13 | — | — | US | claimed |
| US-10760129-B2 | Th17 differentiation markers for acne and uses thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-09-01 | — | — | US | claimed |
| US-20180217130-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | MADRIGAL PHARMACEUTICALS INC (US) | 2018-08-02 | — | — | US | claimed |
| US-20180092923-A1 | METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS | BIOMARIN PHARMACEUTICAL INC. | 2018-04-05 | — | — | US | claimed |
| US-9910031-B2 | Compositions and methods for modulating c-Rel-dependent cytokine production | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-20160326590-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-11-10 | — | — | US | claimed |
| US-20160207994-A1 | MODULATORS OF IL-12 AND/OR IL-23 FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITAT ZURICH (CH) | 2016-07-21 | — | — | US | claimed |
| US-20140349866-A1 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-27 | — | — | US | claimed |
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | claimed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | claimed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | claimed |
| WO-2007100631-A9 | COMPOSITIONS AND METHODS FOR MODULATING CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS CORP (US) | 2007-11-01 | — | — | WO | claimed |
| WO-2007100631-A2 | COMPOSITIONS AND METHODS FOR MODULATING CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1458687-A4 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | claimed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | PIKFYVE 3825/4885TYK2 2409/4885SYK 3624/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | PIKFYVE 3825/4885TYK2 2409/4885SYK 3624/4885 |
| US-20160207994-A1 | MODULATORS OF IL-12 AND/OR IL-23 FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | IL23R, IL2RA, IL1RN | PIKFYVE 3417/4885TYK2 4069/4885SYK 3342/4885 |
| US-20250144107-A1 | USE OF A PIKFYVE INHIBITOR IN COMBINATION WITH IMMUNOTHERAPY | PIKFYVE, LCK, PBK | PIKFYVE 1/4885TYK2 118/4885SYK 111/4885 |
| US-20180092923-A1 | METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, MAN2B1 | PIKFYVE 1535/4885TYK2 4587/4885SYK 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.